References

  1. Barfield R, Hill DA, Hoffer FA, Tekautz T, Spunt SL. Retroperitoneal paraganglioma Med. Pediatr Oncol. 2002; 39(2): 120-124. PubMed | Google Scholar

  2. Scholz T, Schulz C, Klose S, Lehnert H. Diagnostic management of benign and malignant pheochromocytoma. Experimental and Clinical Endocrinology & Diabetes. 2007 Mar; 115(3): 155-15. PubMed | Google Scholar

  3. De Lellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours: pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press. 2004; 57-66. Google Scholar

  4. Cascon A, Pita G, Burnichon N, Landa I, Lopez-Jiménez E, Montero-Conde C, Leskela S, Leandro-Garcia LJ, Leton R, Rodriguez-Antona C et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. Journal of Clinical Endocrinology and Metabolism. 2009; 94(5): 1701-1705. PubMed | Google Scholar

  5. Judith Favier, Laurence Amar, Anne-Paule Gimenez-Roqueplo. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology. 2015 Fev; 11(2): 101-111. PubMed | Google Scholar

  6. Corssmit EP, Romijn JA. Clinical management of paraganglioma. Eur J Endocrinol. 2014 Dec; 171(6): R231-43. PubMed

  7. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2014 Jun; 99 (6): 1915-1942. PubMed | Google Scholar

  8. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014 Sep; 171 (3): R111-22. PubMed | Google Scholar

  9. Gabriele Parenti, Benedetta Zampetti, Elena Rapizzi, Tonino Ercolino, Valentino Giachè, Massimo Mannelli. Updated and New Perspectives on Diagnosis, Prognosis and Therapy of Malignant Pheochromocytoma/Paraganglioma. J Oncol. 2012 Jul; 2012: 872713. PubMed | Google Scholar

  10. Van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and pheochromo- cytoma: systematic review and meta-analysis. Clinical Endocrinology. 2014 Apr; 80(4): 487-501. PubMed | Google Scholar

  11. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochro- mocytoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2008 Dec; 52 (4):334-340. PubMed | Google Scholar

  12. Fishbein L, Bonner L, Torigian DA, Nathanson KL, Cohen DL, Pryma D, Cengel KA. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and-neck paraganglioma: combination with 131I-MIBG. Horm Metab Res. 2012 May; 44(5): 405-10. PubMed | Google Scholar

  13. Niemeijer ND, Alblas G, Van Hulsteijn LT, Dekkers OM, Corssmit EPM. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clinical Endocrinology. 2014 Nov; 81(5): 642-651. PubMed | Google Scholar

  14. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, De'andreis D, Borget I, Loriot C, Chougnet C et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pechromocytoma or paragangliom. International Journal of Cancer. 2014 Dec 1; 135(11): 2711-20. PubMed | Google Scholar

  15. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic para-gangliomas. Journal of Clinical Endocrinology and Metabolism. 2012 Nov; 97(11): 4040-4050. PubMed | Google Scholar

  16. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer. 2012 Dec; 15; 118(24): 6162-6170. PubMed | Google Scholar

  17. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer. 2006 Jun; 13(2): 535-540. PubMed | Google Scholar